Drug Profile
PB 1023
Alternative Names: GLP-1-ELP-120; Glymera; PB1023Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator PhaseBio Pharmaceuticals
- Class Antihyperglycaemics; Glucagon-like peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-II for Type 2 diabetes mellitus in USA (SC)
- 22 Feb 2023 Discontinued - Preclinical for Type 2 diabetes mellitus (Combination therapy) in USA (SC)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus(Combination therapy) in USA (SC, Injection)